Bioinformatics

Researchers Identify Gene That Predicts Breast Cancer Patients' Treatment Outcomes

Retrieved on: 
Wednesday, March 23, 2022
Doctor of Science, Risk, Johns Hopkins University, DNA, Roswell Park Comprehensive Cancer Center, National Cancer Institute, Lists of diseases, Molecular epidemiology, Anthracycline, UACA, Association, Upstate New York, List of Nature Research journals, Doctor of Philosophy, Woman, Paper, Associate, National Center for Complementary and Integrative Health, National Institutes of Health, Bioinformatics, Genome, Johns Hopkins Center for Health Security, NIH, Oncology, Hope, National, Marker beacon, Breast cancer, CIDR, Department, Division, National Center for Advancing Translational Sciences, Patient, Toxicity, Dietary supplement, Pharmaceutical industry, Medical imaging, Research, Biostatistics

"Our study uncovered a gene that strongly associates with a patient's outcome after treatment with anthracyclines and anti-HER2 therapy, which may help oncologists formulate appropriate treatment strategies for patients with breast cancer based on their genetic makeup."

Key Points: 
  • "Our study uncovered a gene that strongly associates with a patient's outcome after treatment with anthracyclines and anti-HER2 therapy, which may help oncologists formulate appropriate treatment strategies for patients with breast cancer based on their genetic makeup."
  • To make this discovery, the cancer researchers analyzed the DNA of 3,973 breast cancer patients from the Pathways Study, a large, multiethnic study of women undergoing treatment for breast cancer at Kaiser Permanente Northern California.
  • The findings also highlight the potential of targeting both the UACA gene and the Par-4 pathway as new approaches to improving outcomes of patients with breast cancer.
  • "It is amazing that we started with an agnostic search across the genome for genetic markers associated with breast cancer outcomes and identified UACA as a promising gene predictive of treatment outcomes for two commonly used agents for breast cancer," adds Dr. Yao.

Element Biosciences Launches the AVITI™ System to Democratize Access to Genomics

Retrieved on: 
Monday, March 14, 2022
Health, Genetics, Other Health, Other Science, Research, Science, Biotechnology, Roche, Industry, Genomics, Senior, NGS, Research, Workflow, Â, Bioinformatics, Avidity, Bureau of Oceans and International Environmental and Scientific Affairs, Element, Entrepreneurship, New England Biolabs, Acquisition, Efficiency, Art, QIAGEN, Technology, Freedom, CEO, Agilent Technologies, NEB, Video game console, Computer data storage, Fine chemical

The AVITI System operates two random access flow cells that enable independent run start flexibility of each flow cell, and the AVITI operating software features tunable read throughput control for additional run time flexibility.

Key Points: 
  • The AVITI System operates two random access flow cells that enable independent run start flexibility of each flow cell, and the AVITI operating software features tunable read throughput control for additional run time flexibility.
  • These partners include, in alphabetical order: Agilent Technologies , Dovetail Genomics , Fabric Genomics , Genoox , Google DeepVariant , Jumpcode Genomics , New England Biolabs (NEB) , QIAGEN , Roche , Sentieon , 10x Genomics , and Watchmaker Genomics .
  • With the launch of our AVITI System, Element is delivering on its vision to dramatically expand access to high quality, low cost, easy-to-use genomics tools, said Molly He, Ph.D., CEO and Co-Founder of Element Biosciences.
  • Element is now accepting orders for the AVITI System, with shipments expected to begin in Q2 2022.

Kiromic BioPharma Provides Business Update and Reports Third Quarter 2021 Financial Results

Retrieved on: 
Friday, March 11, 2022
Other Health, Research, General Health, Pharmaceutical, Oncology, Medical Devices, Genetics, Clinical Trials, Science, Biotechnology, Other Science, Health, NASDAQ, Biomarker, Industry, Government, Solution, Kirom Bukhoroi, Twitter, University, MD Anderson Cancer Center, D, Drug development, Private Securities Litigation Reform Act, Company, Research, U.S. Securities and Exchange Commission, FDA, Machine learning, LLC, Cancer, Board, Acquisition, National Cancer Institute, Securities Exchange Act of 1934, Proteogenomics, Artificial intelligence, National, Inc., Disclosure, Security (finance), Form, Johns Hopkins School of Medicine, COVID-19, Drug discovery, SEC, Committee, Operation, Proteome, Terminology, Forward-looking statement, LinkedIn, Medical device, Pharmaceutical industry, Animal, Audit, Bioinformatics

We believe that we made meaningful progress during the third quarter of 2021 with our corporate developments and with our chemical manufacturing and control manufacturing processes.

Key Points: 
  • We believe that we made meaningful progress during the third quarter of 2021 with our corporate developments and with our chemical manufacturing and control manufacturing processes.
  • The Company was precluded from filing its Form 10-Q in November 2021 pending completion of the internal review, stated Pietro Bersani, interim Chief Executive Officer of Kiromic BioPharma.
  • Kiromics growing machine learning platform is designed to identify new therapeutic opportunities, prioritizing T and B cell targets, and accelerate development.
  • Completion of InSilico Solutions, LLC Acquisition: On July 26, 2021, we announced the completion of the Insilico Solutions, LLC acquisition.

Tonix Pharmaceuticals Announces Appointment of Jeffrey Rosenfeld, Ph.D., as Executive Director, Genomics and Bioinformatics

Retrieved on: 
Wednesday, March 9, 2022
SL2, Schizophrenia, University, U.S. Securities and Exchange Commission, Therapy, Omicron, Medical laboratory, RPV, Private Securities Litigation Reform Act, Psychiatry, Degenerative disease, Central nervous system, Severe acute respiratory syndrome coronavirus 2, Smallpox, Government, Drug development, Cocaine, Company, Cold Spring Harbor Laboratory, FDA, Failure, Autism, CNS, Infection, GLOBE, Pathology, SEC, Vaccine, Assistant, Fibromyalgia, Research, Rutgers Cancer Institute of New Jersey, Cold, Annual report, Neurology, Autoimmunity, Cancer, Genomics, Hydrogen chloride, Pain, Risk, Security (finance), Long COVID, Disease, Nasdaq, Tablet, Achievement, Bioinformatics, CD40, SL, COVID-19, Intelligence, Science Publishing Group, Pharmaceutical industry, New York University, Biotechnology, Tonix Pharmaceuticals, Biology

CHATHAM, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Jeffrey Rosenfeld, Ph.D., as its new Executive Director, Genomics and Bioinformatics.

Key Points: 
  • CHATHAM, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Jeffrey Rosenfeld, Ph.D., as its new Executive Director, Genomics and Bioinformatics.
  • Dr. Rosenfeld brings substantial genomics expertise to Tonix that will support our efforts in pharmacogenomics and companion diagnostics, said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.
  • I am excited to join Tonix to lead the Company's efforts to integrate genomics with clinical trials, said Dr. Rosenfeld.
  • Dr. Rosenfeld has a record of achievement in genomics and bioinformatics.

Premier Medical Laboratory Services Hires Bioinformatics Expert, Dr. Daniel Hughes

Retrieved on: 
Tuesday, February 15, 2022
Knowledge, Columbia University Mailman School of Public Health, Columbia University, National Institute of Allergy and Infectious Diseases, Oncogenomics, CEO, High Performance Computing Modernization Program, Health, Science, Infection, European Bioinformatics Institute, LCMS, Doctor of Philosophy, Maharashtra Legislative Assembly, Genome, NIAID, NGS, University, Human Genome Sequencing Center, Complex, Baylor College of Medicine, Medical school, Technology, Baylor University, Premier Medical Group, COLA, CLIA, VectorBase, Physician, Genetics, Research, DNA sequencing, Genomics, COVID-19, Norwich Pharma Services, Molecular biology, Genome informatics, Industry, National Institute, Organization, Medical device, Medicine, Pharmaceutical industry, Bioinformatics

GREENVILLE, S.C., Feb. 15, 2022 /PRNewswire/ --Dr. Daniel Hughes, M2Gen's former Director of Cancer Knowledge Base and Pharma Services, has joined Premier Medical Laboratory Services (PMLS) as the Director of Bioinformatics.

Key Points: 
  • GREENVILLE, S.C., Feb. 15, 2022 /PRNewswire/ --Dr. Daniel Hughes, M2Gen's former Director of Cancer Knowledge Base and Pharma Services, has joined Premier Medical Laboratory Services (PMLS) as the Director of Bioinformatics.
  • "We are completely honored to have Daniel join the team," said Kevin Murdock, CEO of Premier Medical Laboratory Services.
  • Now, he joins Premier Medical Laboratory Services as the Director of Bioinformatics.
  • Premier Medical Laboratory Services is fully certified by all major accrediting organizations including Clinical Laboratory Improvement Amendments (CLIA) and COLA.

SEC Proposes Amendments to Include Significant Treasury Markets Platforms Within Regulation ATS

Retrieved on: 
Wednesday, January 26, 2022
Bangladesh Securities and Exchange Commission, Comment, Regulation, Processor register, SEC, ATS, Alternative trading system, Commission, Technology, Treasury, Security (finance), Federal Register, SCI, Bioinformatics, Awka South, Financial adviser

It would extend Regulation ATS to include systems that offer the use of non-firm trading interest and provide protocols to bring together buyers and sellers for trading any type of security.

Key Points: 
  • It would extend Regulation ATS to include systems that offer the use of non-firm trading interest and provide protocols to bring together buyers and sellers for trading any type of security.
  • These Communication Protocol Systems would be required to either register as exchanges or register as broker-dealers and comply with Regulation ATS.
  • Todays proposal includes the core elements of the 2020 proposal, including registration of certain interdealer brokers (IDBs) in the Treasury markets.
  • It would bring Treasury trading platforms with significant volume under Regulation Systems Compliance Integrity (SCI), a rule that protects for the resiliency of technology infrastructure.

Scipio bioscience Launches Commercialization in Europe of Asteria©, its RNA Sequencing Kit

Retrieved on: 
Wednesday, January 26, 2022
Stem Cells, Software, Biotechnology, Pharmaceutical, Health, Technology, Clinical Trials, Other Technology, COVID-19, Immune system, RNA, Population, Collection, D, Research, Pathology, Cell, Cancer, Adoption, CEO, Science, Technology, Laboratory, Bioinformatics, Transcriptome, Vaccine, Fine chemical, Pharmaceutical industry, Asteria©, Scipio bioscience, ASTERIA©, SCIPIO BIOSCIENCE

With its Asteria hydrogel technology, Scipio bioscience is creating a new standard in the field of RNA sequencing, a market estimated at $4.2 billion in 2024.

Key Points: 
  • With its Asteria hydrogel technology, Scipio bioscience is creating a new standard in the field of RNA sequencing, a market estimated at $4.2 billion in 2024.
  • For Pierre Walrafen, co-founder and CEO of Scipio bioscience, "The Asteria Scipio bioscience kit revolutionizes access to RNA sequencing.
  • The Asteria individual cell sequencing kit is the first product in a range designed to provide turnkey solutions to researchers.
  • Scipio bioscience has benefited from the support of the Programme d'Investissement d'Avenir of the ParisRegion and Bpifrance, and has received significant private funding.

Global CRISPR/Cas9 Genome Editing Products Market Report: Market Analysis, Survey Data, Toolbox for CRISPR/Cas9 Experiments, Future Needs, Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 13, 2022
Health, Genetics, DNA, Therapy, Market, Research, Technology, Plant, Human, Animal, Cas9, Bioinformatics, CRISPR, Retail, Fine chemical

The "The Market for CRISPR/Cas9 Genome Editing Products" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Market for CRISPR/Cas9 Genome Editing Products" report has been added to ResearchAndMarkets.com's offering.
  • This report provides an in-depth and up-to-date look into scientists' use of the genome editing tool, CRISPR/Cas9.
  • Our survey reveals that while the market is growing steadily, there are challenges confronting suppliers.
  • Consequently, the genome editing market, of which CRISPR/Cas9 already accounts for more than half, is poised to expand rapidly over the coming years.

10x Genomics, Integrated DNA Technologies (IDT), and Sartorius Receive Top Honors at Life Science Industry Awards

Retrieved on: 
Wednesday, December 8, 2021
Research, Medicine, Drug discovery, Bioinformatics, IMV, Spiral Dynamics, Gene, Virginia Institute for Forensic Science and Medicine, Multimedia, Diagnosis, Pharmaceutical industry, Fine chemical

Since 2002, the Life Science Industry Awards have recognized manufacturers of the "tools of science" that help advance biological research and drug discovery.

Key Points: 
  • Since 2002, the Life Science Industry Awards have recognized manufacturers of the "tools of science" that help advance biological research and drug discovery.
  • Traditionally, the Life Science Industry Awards have been a bi-annual event where thousands of life scientists nominate and vote for the best performing supplier in 10 distinct customer support, service and communications categories.
  • Beginning in 2019, the Life Science Industry Awards have expanded to include three new categories to recognize the most innovative new products released this year.
  • BioInformatics Inc., part of Science and Medicine Group, is the premier research and advisory firm serving the life science and analytical instrument industries.

14 Companies Nominated for a Life Science Industry Award for Innovation

Retrieved on: 
Thursday, December 2, 2021
Medicine, Virginia Institute for Forensic Science and Medicine, Research, Bioinformatics, Drug discovery, Innovation, IMV, Spiral Dynamics, Pharmaceutical industry, Fine chemical

ARLINGTON, Va., Dec. 2, 2021 /PRNewswire-PRWeb/ --BioInformatics Inc., part of Science and Medicine Group, the leading research and advisory firm serving the life science tools market, today announced that 14 companies have been nominated for a Life Science Industry Award for launching one of the most innovative new products in 2021.

Key Points: 
  • ARLINGTON, Va., Dec. 2, 2021 /PRNewswire-PRWeb/ --BioInformatics Inc., part of Science and Medicine Group, the leading research and advisory firm serving the life science tools market, today announced that 14 companies have been nominated for a Life Science Industry Award for launching one of the most innovative new products in 2021.
  • Since 2002, the Life Science Industry Awards have recognized manufacturers of the "tools of science" that help advance biological research and drug discovery.
  • Traditionally, the Life Science Industry Awards have been a bi-annual event where thousands of life scientists nominate and vote for the best performing supplier in 10 distinct customer support, service and communications categories.
  • Here are the 2021 Nominees for the Life Science Industry Awards Innovation:
    The winners of the 2021 Life Science Industry Awards for Innovation will be announced via webinar on December 8th, 2021 at 2:00pm EST.